KM 001 - Kamari Pharma
Alternative Names: KM-001 - Kamari PharmaLatest Information Update: 28 Sep 2025
At a glance
- Originator Kamari Pharma
- Class Anti-inflammatories; Antipruritics; Calcium regulators; Keratolytics; Skin disorder therapies; Small molecules
- Mechanism of Action TRPV3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Ichthyosis; Palmoplantar keratoderma
- No development reported Pachyonychia congenita; Pruritus
Most Recent Events
- 28 Sep 2025 No recent reports of development identified for phase-I development in Pachyonychia-congenita(In the elderly, In adults) in United Kingdom (Topical, Cream)
- 28 Sep 2025 No recent reports of development identified for phase-I development in Palmoplantar keratoderma(In the elderly, In adults) in United Kingdom (Topical, Cream)
- 28 Aug 2025 No recent reports of development identified for phase-I development in Pruritus in Germany (Topical)